logo
  

Panera Bread Q2 Profit Decreases; Reiterates Full Year Outlook - Quick Facts

Panera Bread Company (PNRA) reported net income of $42 million, or $1.60 per share, for second quarter 2015 compared to $49 million, or $1.82 per share, prior year. Earnings per share, excluding certain items, was $1.61, for the quarter.

On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $1.63 for the quarter. Analysts' estimates typically exclude special items.

Revenue increased 7% to $677 million. Analysts expected revenue of $679.07 million for the quarter. Company-owned comparable net bakery-cafe sales increased 2.4%.

The company reiterated its full year fiscal 2015 earnings per share growth target of flat to down mid- to high-single digits when compared to full year fiscal 2014, excluding charges in fiscal 2015 for the company's refranchising initiative and certain items for full year fiscal 2014. The company reiterated its targeted range for fiscal 2015 company-owned comparable net bakery-cafe sales growth of 2.0% to 3.5%.

The company announced that company-owned comparable net bakery-cafe sales in the first 27 days of fiscal third quarter 2015 were up 4.7%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT